Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 38

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 38
---
One of the ways we have
grown our pipeline and business in the past is through strategic acquisitions of other businesses, product candidates, and technologies.
We may, from time to time, evaluate additional acquisition opportunities, and may, in the future, strategically make further acquisitions
of, and investments in, businesses, compounds, products and technologies when we believe the opportunity is advantageous to our prospects,
such as the acquisition of eRapa and tolimidone. There can be no assurance that in the future we will be able to find appropriate acquisitions
or investments. In connection with these acquisitions or investments, we may:

| • | issue stock that would dilute our shareholders’ percentage of ownership; |

| • | be obligated to make milestone or other contingent or non-contingent payments; |

| • | incur debt and assume liabilities; and/ or |

| • | incur amortization expenses related to intangible assets or incur large and immediate write-offs. |

| 20 |

We also may be unable to find
suitable acquisition candidates and may not be able to complete acquisitions on favorable terms, if at all, or obtain adequate financing
for such acquisitions. If we do complete an acquisition, this may not ultimately strengthen our competitive position or ensure that we
will not be viewed negatively by customers, financial markets or investors. Further, acquisitions could also pose numerous additional
risks to our operations, including:

| • | problems integrating the purchased business, products or technologies without substantial costs, delays 
 or other problems;                                                                                      |

| • | increases to our expenses; |

| • | the failure to have discovered undisclosed liabilities of the acquired asset or company for which we may 
 not be adequately indemnified;                                                                           |

| • | diversion of management’s attention from their day-to-day responsibilities and our core business; |

| • | inability to enforce indemnification and non-compete agreements; |

| • | the failure to successfully incorporate acquired products or technologies into our business; |

| • | the failure of the acquired business, products or technologies to perform as well as anticipated; |

| • | the failure to realize expected synergies and cost savings; |

| • | unexpected safety issues and/or clinical trial failure of the acquisition’s products; |

| • | harm to our operating results or financial condition, particularly during the first several reporting 
 periods after the acquisition is completed;                                                           |

| • | entrance into markets in which we have limited or no prior experience; and |

| • | potential loss of key employees or customers, particularly